ReviewCancers2021
Challenges and Future Perspectives of Immunotherapy in Pancreatic Cancer.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07595172 (A Phase I/II Clinical Trial of NALIRIFOX Combined With Adebrelimab and PULSAR as First-Line Treatment for Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma), which is not on this map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Clinical Trial of NALIRIFOX Combined With Adebrelimab and PULSAR as First-Line Treatment for Locally Advanced Unresectable or Metastatic Pancreatic Ductal Adenocarcinoma
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Advancing precision immunotherapy in advanced pancreatic cancer: a systematic review and meta-analysis of first-line ICI-based combinations.Frontiers in immunology · 2026Pooled it
- T Cell Exhaustion and Activation Markers in Pancreatic Cancer: A Systematic Review.Journal of gastrointestinal cancer · 2024Pooled it
- Prognostic Implications of Intratumoral and Peritumoral Infiltrating Lymphocytes in Pancreatic Ductal Adenocarcinoma.Current oncology (Toronto, Ont.) · 2021Pooled it
- PD-1 blockade plus chemoradiotherapy as preoperative therapy for patients with BRPC/LAPC: A biomolecular exploratory, phase II trial.Cell reports. Medicine · 2023Trial
- Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer.International journal of nanomedicine · 2026Review
- Synergistic antitumor efficacy of a decorin-carrying oncolytic adenovirus combined with chemotherapy in pancreatic cancer.Frontiers in oncology · 2026Article
- Camrelizumab Combined with Gemcitabine and Albumin-Bound Paclitaxel in Pancreatic Cancer Patients with Liver Metastases: A Prospective, Pilot Trial.Drug design, development and therapy · 2026Article
- Immune-Mitochondrial Crosstalk in Pancreatic Adenocarcinoma: Systematic Identification of Prognostic Biomarkers Through Immune Dictionary FrameworkEndocrine, metabolic & immune disorders drug targets · 2026Article
- Survival and pathological response in pancreatic ductal adenocarcinoma after preoperative therapy with PD-1 blockade plus chemoradiotherapy followed by surgical resection.Annals of medicine · 2025Article
- Emerging biomarkers for pancreatic cancer: from early detection to personalized therapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Review
- Pancreatic Cancer: Pathogenesis and Clinical Studies.MedComm · 2025Review
- Suppression of pancreatic cancer proliferation through TXNIP-mediated inhibition of the MAPK signaling pathway.Acta biochimica et biophysica Sinica · 2024Article
- Machine learning-based approach for automated classification of cell and extracellular matrix using nanomechanical properties.Materials today. Bio · 2024Article
- Neoadjuvant chemotherapy may be the best neoadjuvant therapy modality for non-metastatic pancreatic cancer: a population based study.Frontiers in oncology · 2024Article
- Unraveling the potential of CD8, CD68, and VISTA as diagnostic and prognostic markers in patients with pancreatic ductal adenocarcinoma.Frontiers in immunology · 2024Article
- Fibroblasts as Turned Agents in Cancer Progression.Cancers · 2023Review
- PD-1 blockade combined with gemcitabine plus nab-paclitaxel is superior to chemotherapy alone in the management of unresectable stage III/IV pancreatic cancer: a retrospective real-world study.Frontiers in oncology · 2023Article
- IntracellularFrontiers in immunology · 2023Article
- Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma.Frontiers in oncology · 2023Article
- First-in-human study of ONO-4578, an antagonist of prostaglandin ECancer science · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
To date, extensive efforts to harness immunotherapeutic strategies for the treatment of pancreatic ductal adenocarcinoma (PDAC) have yielded disappointing results in clinical trials. These strategies mainly focused on cancer vaccines and immune checkpoint inhibitors alone or in combination with chemotherapeutic or targeted agents. However, the growing preclinical and clinical data sets from these efforts have established valuable insights into the immunological characteristics of PDAC biology. Most notable are the immunosuppressive role of the tumour microenvironment (TME) and PDAC's characteristically poor immunogenicity resulting from tumour intrinsic features. Moreover, PDAC tumour heterogeneity has been increasingly well characterized and may additionally limit a "one-fits-all" immunotherapeutic strategy. In this review, we first outline mechanisms of immunosuppression and immune evasion in PDAC. Secondly, we summarize recently published data on preclinical and clinical efforts to establish immunotherapeutic strategies for the treatment of PDAC including diverse combinatorial treatment approaches aiming at overcoming this resistance towards immunotherapeutic strategies. Particularly, these combinatorial treatment approaches seek to concomitantly increase PDAC antigenicity, boost PDAC directed T-cell responses, and impair the immunosuppressive character of the TME in order to allow immunotherapeutic agents to unleash their full potential. Eventually, the thorough understanding of the currently available data on immunotherapeutic treatment strategies of PDAC will enable researchers and clinicians to develop improved treatment regimens and to design innovative clinical trials to overcome the pronounced immunosuppression of PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.